An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. announced its preliminary financial results for the year ending December 31, 2024, showing a significant increase in total operating income by 29.67% compared to the previous year. Despite this growth, the company reported an operating loss of RMB 133,857.71, which is an improvement from the previous year’s loss. The net loss attributable to the owners of the parent company also decreased, reflecting a better financial performance. The company’s total assets decreased by 4.95%, and equity attributable to owners of the parent company fell by 18.05%. These results indicate a challenging yet improving financial position, which stakeholders should consider cautiously.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in China, operating in the biosciences industry. The company focuses on developing innovative drugs and therapies, and is listed on the Stock Exchange of Hong Kong.
YTD Price Performance: 40.07%
Average Trading Volume: 1,177,260
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$29.55B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.